{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:52:13Z","timestamp":1792180333941,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.04.009","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T01:42:05Z","timestamp":1620438125000},"page":"106-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Response to systemic therapy in fumarate hydratase\u2013deficient renal cell carcinoma"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8256-4376","authenticated-orcid":false,"given":"Lucia","family":"Carril-Ajuria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Colomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-244X","authenticated-orcid":false,"given":"Luigi","family":"Cerbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9125-2275","authenticated-orcid":false,"given":"Carmen","family":"Romero-Ferreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Crouzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Laguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Vicier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"de Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Saldana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1003-1997","authenticated-orcid":false,"given":"Patrick R.","family":"Benusiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Bressac-de Paillerets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Guillaud-Bataille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-2013","authenticated-orcid":false,"given":"Pauline","family":"Gaignard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-6823","authenticated-orcid":false,"given":"Jean-Yves","family":"Scoazec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-3480","authenticated-orcid":false,"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.04.009_bib1","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-13-0304","article-title":"Molecular pathways: fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer","volume":"19","author":"Linehan","year":"2013","journal-title":"Clin Canc Res Off J Am Assoc Canc Res"},{"key":"10.1016\/j.ejca.2021.04.009_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/PAS.0000000000001372","article-title":"A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients","volume":"44","author":"Lau","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2021.04.009_bib3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cge.13014","article-title":"Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers: MULLER et\u00a0al","volume":"92","author":"Muller","year":"2017","journal-title":"Clin Genet"},{"key":"10.1016\/j.ejca.2021.04.009_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5004","article-title":"Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer","volume":"38","author":"Srinivasan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.009_bib5","first-page":"974","volume":"31","author":"Muller","year":"2018","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.ejca.2021.04.009_bib6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/jclinpath-2019-205924","article-title":"Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases","volume":"72","author":"Pan","year":"2019","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ejca.2021.04.009_bib7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10689-014-9735-2","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment","volume":"13","author":"Menko","year":"2014","journal-title":"Fam Cancer"},{"key":"10.1016\/j.ejca.2021.04.009_bib8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2021.04.009_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.04.009_bib10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.04.009_bib11","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdv149","article-title":"First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)","volume":"26","author":"Ravaud","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.04.009_bib12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejca.2016.08.004","article-title":"Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis","volume":"69","author":"Escudier","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.009_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.009_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejca.2017.10.014","article-title":"Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial","volume":"87","author":"Sch\u00f6ffski","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.009_bib15","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.2017.72.2967","article-title":"Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.009_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.619","article-title":"Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer","volume":"38","author":"Suarez Rodriguez","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.009_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial","author":"Choueiri","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.04.009_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.02.001","article-title":"Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: results of the multicentre, open-label, single-arm, phase II AXIPAP trial","volume":"129","author":"Negrier","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.009_bib19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejca.2021.04.009_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/jmg.2010.085068","article-title":"Novel FH mutations in families with\u00a0hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma","volume":"48","author":"Gardie","year":"2011","journal-title":"J Med Genet"},{"key":"10.1016\/j.ejca.2021.04.009_bib21","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-4367","article-title":"Comprehensive molecular characterization and response to therapy in FH-deficient renal cell carcinoma","author":"Gleeson","year":"2021","journal-title":"Clin Canc Res Off J Am Assoc Canc Res"},{"key":"10.1016\/j.ejca.2021.04.009_bib22","series-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","year":"2016"},{"key":"10.1016\/j.ejca.2021.04.009_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4579","article-title":"Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): a retrospective multicenter analysis","volume":"36","author":"Martinez Chanza","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.009_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejca.2018.08.014","article-title":"Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: a retrospective analysis","volume":"104","author":"Campbell","year":"1990","journal-title":"Eur J Canc Oxf Engl"},{"key":"10.1016\/j.ejca.2021.04.009_bib25","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1158\/1078-0432.CCR-15-0375","article-title":"Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of egfr signaling pathways in non-small cell lung cancer","volume":"21","author":"De Rosa","year":"2015","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2021.04.009_bib26","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4143\/crt.2019.086","article-title":"Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: a multicenter retrospective analysis in Korean patients","volume":"51","author":"Choi","year":"2019","journal-title":"Canc Res Treat"},{"key":"10.1016\/j.ejca.2021.04.009_bib27","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.6004\/jnccn.2019.0054","article-title":"NCCN guidelines insights: kidney cancer, version 2.2020: featured updates to the NCCN guidelines","volume":"17","author":"Motzer","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2021.04.009_bib28","article-title":"Open-Label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non\u2013clear cell renal cell carcinoma","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.009_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2020.02.019","article-title":"Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study","volume":"136","author":"de Vries-Brilland","year":"1990","journal-title":"Eur J Canc Oxf Engl"},{"key":"10.1016\/j.ejca.2021.04.009_bib30","series-title":"A phase 2, randomized, open-label study of nivolumab combined with ipilimumab versus standard of care in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma (nccRCC)","author":"Goekbuget","year":"2020"},{"key":"10.1016\/j.ejca.2021.04.009_bib31","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/jmg.2006.041087","article-title":"Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer","volume":"43","author":"Pithukpakorn","year":"2006","journal-title":"J Med Genet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:34Z","timestamp":1760733094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921002409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":31,"alternative-id":["S0959804921002409"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to systemic therapy in fumarate hydratase\u2013deficient renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}